HCV variants

Details HCV variants HCV variants

2001-05-23

2008-03-04

Lucas, Zachariah (Department: 1648)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S069100, C435S070100, C435S320100, C435S235100, C435S239000, C435S005000, C536S023720, C536S024100

Reexamination Certificate

active

07338759

ABSTRACT:
HCV variants are described. The variants include polynucleotides comprising non-naturally occurring HCV sequences and HCV variants that have a transfection efficiency and ability to survive subpassage greater than HCV that have wild-type polyprotein coding regions. Expression vectors comprising the above polynucleotides and HCV variants are also described, as are the provision of cells and host cells comprising the expression vectors. Methods for identifying a cell line that is permissive for infection with HCV are also provided, as are vaccines comprising the above polynucleotides in a pharmaceutically acceptable carrier. Additionally, methods for inducing immunoprotection to HCV in a primate are described, as are methods for testing a compound for inhibiting HCV replication.

REFERENCES:
patent: 4631211 (1986-12-01), Houghten
patent: 5010175 (1991-04-01), Rutter et al.
patent: 5077193 (1991-12-01), Mishiro et al.
patent: 5106726 (1992-04-01), Wang
patent: 5176994 (1993-01-01), Mishiro et al.
patent: 5218099 (1993-06-01), Reyes et al.
patent: 5298394 (1994-03-01), Arima et al.
patent: 5312737 (1994-05-01), Bolling et al.
patent: 5350671 (1994-09-01), Houghton et al.
patent: 5371017 (1994-12-01), Houghton et al.
patent: 5372928 (1994-12-01), Miyamura et al.
patent: 5378814 (1995-01-01), Houghton et al.
patent: 5389528 (1995-02-01), Houghton et al.
patent: 5427909 (1995-06-01), Okamoto et al.
patent: 5428145 (1995-06-01), Okamoto et al.
patent: 5436126 (1995-07-01), Wang
patent: 5443965 (1995-08-01), Reyes et al.
patent: 5527669 (1996-06-01), Resnick et al.
patent: 5538865 (1996-07-01), Reyes et al.
patent: 5550016 (1996-08-01), Okamoto
patent: 5552310 (1996-09-01), Yoshikura et al.
patent: 5576302 (1996-11-01), Cook et al.
patent: 5580718 (1996-12-01), Resnick et al.
patent: 5585258 (1996-12-01), Houghton et al.
patent: 5597691 (1997-01-01), Houghton et al.
patent: 5610054 (1997-03-01), Draper
patent: 5620843 (1997-04-01), Hellings et al.
patent: 5625034 (1997-04-01), Liao et al.
patent: 5625043 (1997-04-01), Priebe et al.
patent: 5641654 (1997-06-01), Maki et al.
patent: 5645983 (1997-07-01), Liao et al.
patent: 5654179 (1997-08-01), Lin
patent: 5656731 (1997-08-01), Urdea
patent: 5667992 (1997-09-01), Casey et al.
patent: 5670152 (1997-09-01), Weiner et al.
patent: 5670153 (1997-09-01), Weiner et al.
patent: 5677124 (1997-10-01), DuBois et al.
patent: 5679342 (1997-10-01), Houghton et al.
patent: 5683864 (1997-11-01), Houghton et al.
patent: 5698390 (1997-12-01), Houghton et al.
patent: 5712088 (1998-01-01), Houghton et al.
patent: 5714596 (1998-02-01), Houghton et al.
patent: 5837463 (1998-11-01), Tanaka et al.
patent: 5874565 (1999-02-01), Rice et al.
patent: 6127116 (2000-10-01), Rice et al.
patent: 6153421 (2000-11-01), Yanagi et al.
patent: 6392028 (2002-05-01), Rice et al.
patent: 6630343 (2003-10-01), Bartenschlager
patent: 2012311 (1990-09-01), None
patent: 0 318 216 (1989-05-01), None
patent: 0 388 232 (1990-09-01), None
patent: 0 510 952 (1992-10-01), None
patent: 0 521 318 (1993-01-01), None
patent: 0 645 451 (1995-03-01), None
patent: 1 267 167 (2002-12-01), None
patent: 2212511 (1989-07-01), None
patent: 6105690 (1994-04-01), None
patent: WO 89/04669 (1989-06-01), None
patent: WO 90/11089 (1990-10-01), None
patent: WO 91/02820 (1991-03-01), None
patent: WO 91/15771 (1991-10-01), None
patent: WO 92/08734 (1992-05-01), None
patent: WO 93/00365 (1993-01-01), None
patent: WO 93/03186 (1993-02-01), None
patent: WO 93/19183 (1993-09-01), None
patent: WO 95/20660 (1995-08-01), None
Yanagi et al. (Virol. (1998) 244, 161-172.
Pietschmann et al., “Persistent and transient replication of full-length hepatitis C virus genomes in cell culture,” Journal of Virology, vol. 76, No. 8, pp. 4008-4021 (Apr. 2002).
BLAST 2 sequences results: Sequence 1 length 1985 and Sequence 2, AJ242652.1.
Bowie et al., Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substutitions, Science, vol. 247 No. 4948, pp. 1306-1310 (Mar. 1990).
Heller et al., “An in vitro model of hepatitis C viron production,” Proceedings of National Academy of Sciences, USA, vol. 102 No. 7, pp. 2579-2583 (Feb. 2005).
Ikeda et al., “Selectable Subgenomic and Genome-Length Dicistronic RNAs Derived from an Infectious Molecular Clone of the HCV-N Strain Hepatatis C Virus Replicate Effciently in Cultured Huh7 Cells,” Journal of Virology, vol. 76 No. 6, pp. 2997-3006 (Mar. 2002).
Blight et al., Efficient replication of hepatatis C virus genotype 1s RNAs in cell culture, Mar. 2003, pp. 3181-3190, Journal Of Virology.
Friebe and Bartenschlager, Genetic analysis of Sequences in the 3′ nontranslated reigon of hepatatis C virus that are important for RNA replication, J Virol, Jun. 2002, pp. 5326-5338.
Guo et al., Effect of alpha interferon on the hepatatis C virus replicon, J Virol, Sep. 2001, pp. 8516-8523.
Ito et al., The 3′ untranslated region of hepatatis C virus RNA enhances translation from an internal ribsomal entry site, J Virol, Nov. 1998, pp. 8789-8796.
Murray et al., Persistent replication of hepatitis C virus replicons expressing the beta-lactamase reporter in subpopulations of highly permissive Huh7 cells, J Virol, 2003, pp. 2928-2935.
Yanagi et al., Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee, Proc Natl Acad Sci USA, 1997, pp. 8738-8743.
Yi and Lemon, Adaptive mutations producing efficient replication of genotype 1a hepatitis D virus RNA in normal Huh7 cells, J Virol, Aug. 2004, pp. 7904-7915.
Yi and Lemon, 3′ nonstranslated RNA signals required for replication of hepatitis C virus RNA, J Virol, Mar. 2003, pp. 3557-3568.
Verma et al., “Gene Therapy—Promises, Problems and Prospects”, Nature, vol. 389, pp. 239-242 (1997).
Eck et al., “Gene-Based Therapy”, The Pharmacological Basis of Therapeutics, Goodman and Gilman, Eds., pp. 77-101 (1996).
Orkin et al., “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy”, NIH (1995). Online at www.nih.gov
ews/panelrep.html.
Houdebine, “Production of Pharmaceutical Proteins From Transgenic Animals”, Journal of Biotechnology, vol. 34, pp. 269-287 (1994).
Lanford et al., “Advances in Model Systems for Hepatitis C Virus Research”, Virology, vol. 293 No. 1, pp. 1-9 (Feb. 2002).
Zhu et al., “Replication of Hepatitis C Virus Subgenomes in Nonhepatic Epithelial and Mouse Hepatoma Cells”, Journal of Virology, vol. 77 No. 17, pp. 9204-9210 (Sep. 2003).
Grobler et al., “Identification of a Key Determinant of Hepatitis C Virus Cell Culture Adaptation in Domain II of NS3 Helicase”, The Journal of Biological Chemistry, vol. 278 No. 19, pp. 16741-16746 (May 2003).
Blight et al., “Highly Permissive Cell Lines for Subgenomic and Genomic Hepatits C Virus RNA Replication”, Journal of Virology, vol. 76 No. 24, pp. 13001-13014 (Dec. 2002).
Chung et al., “Hepatiitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system”, Proceedings of the National Academy of Sciences, USA, vol. 98 No. 17, pp. 9847-9852 (Aug. 2001).
Bartenschlager et al., “Replication of the hepatitis C virsus in cell culture”, Antiviral Research, vol. 60 No. 2, pp. 91-102 (Oct. 2003).
Patent Cooperation Treaty; International Search Report; Jan. 3, 2005.
Ahlquist et al.,Proc. Natl. Acad. Sci. USA81:7066-7070 (1984).
Barton and Flanegan,J. Virol. 67:822-831 (1993).
Ball,J. Virol. 66:2335-2345 (1992).
Battegay et al.,J. Virol69:2462-2470 (1995).
Behrens et al.Embo. J.15:12022 (1996).
Blight and Gowans,Viral Hepatatis Rev.1:143-155 (1995).
Blight et al., “Efficient Initiation of HCV RNA Replication in Cell Culture”,Science, Dec. 8, 2000, vol. 290, pp. 1972-1974.
Blight et al.,Amer. J. Path. 143:1568-1573 (1993).
Boyer and Haenni,J. Gen. Virol. 198:415-426 (1994).
Boyer et al.,J. Hepatol. 32(1 Suppl.) 98-112 (2000).

Affiliated with

Also associated with

Rating

HCV variants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HCV variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HCV variants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3972747